TRABI.BO · BSE
TRANSGENE BIOTEK LTD.
₹2.73
+1.49% (+₹0.04)
Prev. close
₹2.69
Volume
6,468
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About TRANSGENE BIOTEK LTD.
Transgene Biotek Limited, a biotechnology company, provides research and development services for bulk drugs in India. It offers a portfolio of oncology drugs, oral drug delivery, and biogenerics. The company provides TrabiDHA for use in health food, baby food/formula, health supplement, and chicken and animal feed markets; Tacrolimus, a drug that suppresses the immune system and is used to prevent rejection of transplanted organs; and Orlistat (tetrahydrolipstatin), a lipase inhibitor that blocks about one-third of intestinal fat absorption. The company was incorporated in 1990 and is based in Sangareddy, India.
Details
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Koteswara Rao Kanuru
Headquarters
Sangareddy
Website
transgenebiotek.comExchange
View on BSE ↗Key stats
Market cap
₹20.69 Cr
EPS (TTM)
₹-0.21
Beta (1Y · daily vs NIFTY 50)
1.10
Beta (5Y · monthly vs NIFTY 50)
2.11
Shares float
5.06 Cr
EPS · quarter ended Jun 2026
₹-0.05
Financial Performance
01 · Financials
FY23 growth needs FY22 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹5.51 L | ₹23.49 L | ₹26.10 L | ₹21.10 L | |
| EBITDA | ₹-43.49 L | ₹-42.36 L | ₹-34.00 L | ₹-39.40 L |
| ₹-6.01 Cr | ₹-65.55 L | ₹-67.60 L | ₹-1.65 Cr | |
| Diluted EPS | ₹-0.79 | ₹-0.09 | ₹-0.09 | ₹-0.22 |
Total expenses (as filed), Employee benefit expense, Other expenses have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹142.36 Cr | ₹142.33 Cr | ₹144.09 Cr | ₹143.66 Cr | |
| ₹13.11 Cr | ₹14.00 Cr | ₹14.52 Cr | ₹17.14 Cr | |
| Stockholders' equity | ₹11.37 Cr | ₹10.71 Cr | ₹10.03 Cr | ₹8.38 Cr |
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| — | ₹2,000 | ₹46,000 | ₹1.20 Cr | ₹-1.13 L | |
| Investing cash flow | — | ₹-1.23 L | ₹0 | ₹-1.70 Cr | ₹15.00 L |
| — | ₹0 | ₹0 | ₹78.03 L | ₹-36.23 L | |
| Capital expenditure | — | ₹-15,000 | — | ₹-1.70 Cr | — |
| End cash position | — | ₹31,000 | ₹77,000 | ₹28.43 L | ₹6.07 L |
Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Debt issued, Debt repaid, Capital expenditure, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| TRANSGENE BIOTEK LTD. | ₹20.38 Cr | ₹2.76 | — | 2.43 | -19.7% | 2.05 | -19.0% | -37.0% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 26
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Transgene Biote Consolidated June 2026 Net Sales at Rs 0.06 crore, up 21.21% Y-o-Y
Moneycontrol.com · 1 month ago